Why diabetes trial monitoring is a full-time job
Diabetes is one of the largest and most commercially active therapeutic areas in clinical research. With GLP-1 receptor agonists reshaping the cardiometabolic market, SGLT2 inhibitors expanding beyond glucose control into heart failure, CKD, and NASH, and cell therapy approaching commercial reality for Type 1 diabetes, the pipeline moves fast and the competitive stakes are high.
A search for "diabetes" on ClinicalTrials.gov returns thousands of results across Type 1, Type 2, gestational diabetes, LADA, MODY, and diabetic complications (nephropathy, neuropathy, retinopathy). Filtering by phase, sponsor type, and recruitment status, then comparing against yesterday's results to find what's actually new, takes 45 minutes to do manually. DataLookout does it every morning and delivers only the delta.
Key signals that diabetes professionals track:
- New GLP-1/GIP dual agonist Phase 2/3 programs competing with tirzepatide and semaglutide
- SGLT2 inhibitor combination trials in CKD, heart failure, and metabolic syndrome
- Cell therapy and islet transplant programs advancing toward pivotal studies for Type 1 diabetes
- Oral insulin and novel delivery mechanism trials entering Phase 2
- Obesity-diabetes overlap programs, the GLP-1 wave connecting both indications
- Cardiovascular outcomes trials (CVOTs): regulatory-required milestone studies for new agents
- Diabetic kidney disease programs targeting RAAS, endothelin, and novel pathways
Automate your diabetes trial monitoring
Daily change detection in your dashboard. Free plan, no credit card required.
Start FreeA primary completion date pushed out, enrollment cut, or a primary endpoint changed in the last 90 days. Active trials only.
| Trial | Warning signs | Status |
|---|---|---|
| Surveillance of Pancreatic Health After Diabetes Diagnosis NCT06803771 | Primary completion moved at least 1 year 5 months later Primary endpoint(s) modified Enrollment reduced 67% | Recruiting |
251 more on the Trials at Risk page. See which trials →
Phase 2 and Phase 3 trials with a primary completion date in the next 180 days, as ClinicalTrials.gov estimates it today. Active trials only.
| Trial | Scheduled | Phase |
|---|---|---|
| NAD Augmentation in Diabetes Kidney Disease NCT05759468 | Nov 30, 2026 · Estimated | Phase 2 |
103 more on the Completions page. See the calendar →
What DataLookout monitors for diabetes
Configure your profile with condition keywords as broad or specific as your intelligence needs require. Examples for a diabetes watch profile:
- Type 2 diabetes: "Type 2 Diabetes", "T2DM", "insulin resistance", "glycemic control", "metabolic syndrome"
- Type 1 diabetes: "Type 1 Diabetes", "T1DM", "autoimmune diabetes", "islet transplant", "beta cell"
- Mechanism-specific: "GLP-1", "SGLT2", "DPP-4", "GIP", "insulin analog", "amylin"
- Complications: "diabetic nephropathy", "diabetic retinopathy", "diabetic neuropathy", "diabetic foot"
- Phase filter: Phase 2/3 only for commercial intelligence, or all phases for comprehensive research awareness
- Sponsor filter: Industry-sponsored for competitive tracking, all sponsors for full pipeline view
What DataLookout adds to ClinicalTrials.gov
ClinicalTrials.gov RSS feeds tell you that a study record was updated. DataLookout compares each record against the previous day across 14 tracked fields and tells you which one changed and what changed in it, for every Diabetes trial on your watchlist. Each change is marked Stopped, Notable or Minor, so a trial being terminated does not read the same as a few sites being added.
Who uses diabetes trial monitoring
Metabolic disease pharma BD and strategy teams
BD teams at cardiometabolic-focused pharmaceutical companies track the diabetes pipeline to identify in-licensing opportunities, anticipate competitive threats from GLP-1 next-generation programs, and inform pipeline investment decisions. The SGLT2 and GLP-1 expansions into heart failure, obesity, and CKD have made competitive intelligence across the metabolic disease space essential for any player in the field.
Endocrinology-focused biotech analysts and investors
Investors covering metabolic disease use trial registrations as early signals. A new Phase 3 CVOT start or a Phase 2 diabetes prevention trial registering can precede material valuation events. Daily monitoring of the diabetes pipeline ensures analysts catch meaningful developments before they become widely reported.
Diabetes-focused CROs and clinical operations teams
Contract research organizations and sponsors conducting diabetes trials track new competitor trials to understand competitive enrollment dynamics, particularly relevant in therapeutic areas like NASH/diabetes overlap where patient pools are shared. Understanding which new trials are opening for enrollment affects feasibility planning.
Diabetes patient advocacy organizations
Organizations like the American Diabetes Association, JDRF (T1D focused), and disease-specific foundations use clinical trial awareness to connect patients with appropriate studies. For Type 1 diabetes patients seeking options beyond current standard of care, including beta cell preservation and transplant programs, timely trial awareness is directly meaningful.
Frequently asked questions
How current is the diabetes trial data?
Our pipeline fetches from ClinicalTrials.gov every morning. Studies posted or updated in the preceding 24 hours appear in that day's digest. ClinicalTrials.gov is updated as sponsors register new trials or submit protocol amendments, typically within 24–48 hours of the change.
Can I track Type 1 and Type 2 diabetes separately?
Yes. On Pro ($49/month, or $490/year), you can save up to 10 searches, for example, one tracking T1D cell therapy programs and another monitoring T2DM GLP-1/SGLT2 combination trials, each delivering a focused daily digest.
Does DataLookout cover diabetic complications trials?
Yes. Adding keywords like "diabetic nephropathy", "diabetic retinopathy", or "peripheral neuropathy" to your profile will surface trials specifically targeting diabetes complications. These are often distinct programs from glycemic control trials.
Does DataLookout include obesity trials?
Yes, obesity and metabolic syndrome trials are included when you add relevant keywords. Given the GLP-1 overlap between obesity and diabetes indications, many professionals monitor both in a combined profile.
3689 active trials, 1873 recruiting.
Industry sponsors run 584 of these trials. The rest are run by universities, hospitals, government bodies and other non-commercial sponsors. The table below lists the 5 largest of 316.
| Top industry sponsor | Active trials |
|---|---|
| Novo Nordisk | 36 |
| Eli Lilly and Company | 28 |
| AstraZeneca | 15 |
| Sanofi | 11 |
| Gan & Lee Pharmaceuticals. | 10 |
| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| INcreasing the Uptake of DSMES Program and Addressing Social Needs in… NCT07296211 | Recruiting | Recruitment opened | 2026-11-14 |
| Studying Phenotypes of Gestational Diabetes Mellitus in an Asian Pregnant Cohort NCT06542718 | Active, Not Recruiting | Study completion pushed from Jul 1, 2026 to Jun 2027 | 2026-11-14 |
| Implementation Trial In patieNts With rEnal failuRe and diAbetes for Major… NCT07634718 | Recruiting | Recruitment opened | 2026-11-14 |
| A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control… NCT07754461 | Recruiting | Trial sites expanded: 101 → 121 locations | 2026-11-14 |
| A Study of SA030 Injection in Overweight/Obese Participants With or Without… NCT07479862 | Recruiting | Trial arms changed: 2 → 3 | 2026-11-14 |
Each trial page shows every change DataLookout has recorded for that trial.
DataLookout checks ClinicalTrials.gov every day and records what changed on each trial: status, enrollment, phase, primary endpoint, completion dates, sites, sponsor, and the stated reason a trial stopped. Add a sponsor or a disease to your watchlist, or save any search, and the changes arrive in a daily or weekly email digest.
Free, $0 forever: 1 sponsor + 1 disease watchlist, 1 saved search in your email digest, track up to 5 individual trials, daily change detection, Trials at Risk (top 2 trials). No credit card.
Pro, $49/month or $490/year: 10 sponsor + 10 disease watchlists, 10 saved searches in your email digest, track up to 25 individual trials, full Trials at Risk list, Completions calendar, landscape reports, CSV export.